🚀 VC round data is live in beta, check it out!
Supriya Lifescience Valuation Multiples
Discover revenue and EBITDA valuation multiples for Supriya Lifescience and similar public comparables like Shattuck Labs, Lyell Immunopharma, Boan Biotech, Avalon Pharma and more.
Supriya Lifescience Overview
About Supriya Lifescience
Supriya Lifescience Ltd is a manufacturer of Active Pharmaceutical Ingredients. It is focused on diverse therapeutic segments such as antihistamines, analgesics, anaesthetics, vitamins, anti-asthmatic, and anti-allergic.
Founded
2008
HQ
Employees
515
Website
Financials (LTM)
EV
$554M
Supriya Lifescience Financials
Supriya Lifescience reported last 12-month revenue of $91M and EBITDA of $30M.
In the same LTM period, Supriya Lifescience generated $30M in EBITDA and $22M in net income.
Revenue (LTM)
Supriya Lifescience P&L
In the most recent fiscal year, Supriya Lifescience reported revenue of $82M and EBITDA of $31M.
Supriya Lifescience expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $91M | XXX | $82M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $42M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 52% | XXX | XXX | XXX |
| EBITDA | $30M | XXX | $31M | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 37% | XXX | XXX | XXX |
| EBIT Margin | 31% | XXX | 35% | XXX | XXX | XXX |
| Net Profit | $22M | XXX | $22M | XXX | XXX | XXX |
| Net Margin | 24% | XXX | 27% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Supriya Lifescience Stock Performance
Supriya Lifescience has current market cap of $565M, and enterprise value of $554M.
Market Cap Evolution
Supriya Lifescience's stock price is $7.02.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $554M | $565M | 0.5% | XXX | XXX | XXX | $0.27 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSupriya Lifescience Valuation Multiples
Supriya Lifescience trades at 6.1x EV/Revenue multiple, and 18.2x EV/EBITDA.
EV / Revenue (LTM)
Supriya Lifescience Financial Valuation Multiples
As of April 20, 2026, Supriya Lifescience has market cap of $565M and EV of $554M.
Equity research analysts estimate Supriya Lifescience's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Supriya Lifescience has a P/E ratio of 25.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $565M | XXX | $565M | XXX | XXX | XXX |
| EV (current) | $554M | XXX | $554M | XXX | XXX | XXX |
| EV/Revenue | 6.1x | XXX | 6.8x | XXX | XXX | XXX |
| EV/EBITDA | 18.2x | XXX | 18.1x | XXX | XXX | XXX |
| EV/EBIT | 19.9x | XXX | 19.7x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 13.0x | XXX | XXX | XXX |
| P/E | 25.9x | XXX | 25.6x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 14.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Supriya Lifescience Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Supriya Lifescience Margins & Growth Rates
Supriya Lifescience's revenue in the last 12 month grew by 20%.
Supriya Lifescience's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.
Supriya Lifescience's rule of 40 is 54% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Supriya Lifescience's rule of X is 85% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Supriya Lifescience Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 20% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 34% | XXX | 37% | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | (1%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 54% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 85% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 21% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Supriya Lifescience Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Supriya Lifescience | XXX | XXX | XXX | XXX | XXX | XXX |
| Shattuck Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Lyell Immunopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Boan Biotech | XXX | XXX | XXX | XXX | XXX | XXX |
| Avalon Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fulcrum Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Supriya Lifescience M&A Activity
Supriya Lifescience acquired XXX companies to date.
Last acquisition by Supriya Lifescience was on XXXXXXXX, XXXXX. Supriya Lifescience acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Supriya Lifescience
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialSupriya Lifescience Investment Activity
Supriya Lifescience invested in XXX companies to date.
Supriya Lifescience made its latest investment on XXXXXXXX, XXXXX. Supriya Lifescience invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Supriya Lifescience
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Supriya Lifescience
| When was Supriya Lifescience founded? | Supriya Lifescience was founded in 2008. |
| Where is Supriya Lifescience headquartered? | Supriya Lifescience is headquartered in India. |
| How many employees does Supriya Lifescience have? | As of today, Supriya Lifescience has over 515 employees. |
| Is Supriya Lifescience publicly listed? | Yes, Supriya Lifescience is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Supriya Lifescience? | Supriya Lifescience trades under SUPRIYA ticker. |
| When did Supriya Lifescience go public? | Supriya Lifescience went public in 2021. |
| Who are competitors of Supriya Lifescience? | Supriya Lifescience main competitors are Shattuck Labs, Lyell Immunopharma, Boan Biotech, Avalon Pharma. |
| What is the current market cap of Supriya Lifescience? | Supriya Lifescience's current market cap is $565M. |
| What is the current revenue of Supriya Lifescience? | Supriya Lifescience's last 12 months revenue is $91M. |
| What is the current revenue growth of Supriya Lifescience? | Supriya Lifescience revenue growth (NTM/LTM) is 20%. |
| What is the current EV/Revenue multiple of Supriya Lifescience? | Current revenue multiple of Supriya Lifescience is 6.1x. |
| Is Supriya Lifescience profitable? | Yes, Supriya Lifescience is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Supriya Lifescience? | Supriya Lifescience's last 12 months EBITDA is $30M. |
| What is Supriya Lifescience's EBITDA margin? | Supriya Lifescience's last 12 months EBITDA margin is 34%. |
| What is the current EV/EBITDA multiple of Supriya Lifescience? | Current EBITDA multiple of Supriya Lifescience is 18.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.